Comprehensive Peptide Glossary

Comprehensive Peptide Glossary

The Healius peptide glossary is a working reference for researchers, quality teams and anyone reading a Certificate of Analysis who wants a precise, concise definition of a peptide term. The 75 entries below cover peptide structure and chemistry, peptide classes, synthesis and modification, analytical testing, storage and reconstitution, research pharmacology, and regulatory terminology. Every definition is written by the Healius lab team and cross-referenced to the method or mechanism the term describes. For in vitro research only. Healius peptides are not for human or veterinary use.

Peptide structure and chemistry

Peptide

A peptide is a short chain of amino acids linked by peptide bonds. Peptides are distinguished from proteins by length: peptides typically contain between 2 and 50 amino acid residues, while proteins contain more than 50. The body synthesises peptides naturally (as hormones, neuropeptides and signaling molecules) and peptides can be produced synthetically by solid-phase peptide synthesis for research and therapeutic use.

Amino acid

An amino acid is the molecular building block of peptides and proteins. Each amino acid contains a central alpha carbon bonded to an amino group (NH2), a carboxyl group (COOH), a hydrogen atom, and a variable side chain (R group) that determines its chemical properties. The 20 standard amino acids encoded by DNA are combined in unique sequences to produce every peptide found in biology. Non-natural amino acids are also used in research peptides to introduce stability or modify activity.

Peptide bond

A peptide bond is the covalent amide bond that links one amino acid to the next in a peptide chain. It is formed by a condensation reaction between the carboxyl group of one amino acid and the amino group of the next, releasing a water molecule. Peptide bonds are planar, rigid, and confer the directional backbone structure that defines all peptides and proteins.

Residue

A residue is a single amino acid within a peptide chain. The term reflects what remains after water is removed during peptide bond formation. Peptide sequences are described by counting residues from the N-terminus to the C-terminus, with each residue contributing its side chain to the overall properties of the peptide.

N-terminus

The N-terminus (amino terminus) is the start of a peptide chain where the free amino group is exposed. By convention, peptide sequences are written with the N-terminus on the left. The N-terminus is chemically reactive and is a common site for modifications such as acetylation or pegylation that affect peptide stability and pharmacokinetics.

C-terminus

The C-terminus (carboxy terminus) is the end of a peptide chain where the free carboxyl group is exposed. Peptide sequences are written with the C-terminus on the right. The C-terminus is another common site for modification, particularly amidation, which masks the free carboxyl and alters both stability and biological activity.

Primary structure

Primary structure is the linear sequence of amino acid residues in a peptide, read from N-terminus to C-terminus. Primary structure is what is synthesised in solid-phase peptide synthesis and what is confirmed by mass spectrometry during quality control. Every other level of peptide structure is derived from the primary sequence.

Secondary structure

Secondary structure refers to local three-dimensional folding patterns within a peptide, primarily alpha helices and beta sheets, stabilised by hydrogen bonds between backbone atoms. Secondary structure depends on the primary sequence and the solvent environment. Some research peptides adopt stable secondary structures in solution and rely on them for biological activity.

Tertiary structure

Tertiary structure is the overall three-dimensional shape of a folded peptide or protein, produced by interactions between side chains such as hydrophobic packing, salt bridges, hydrogen bonds, and disulfide bonds. Most short research peptides do not adopt stable tertiary structures in solution, but larger peptides and proteins depend on correct tertiary folding for activity.

Quaternary structure

Quaternary structure is the assembly of two or more peptide or protein subunits into a functional complex. Most research peptides are monomeric and do not have quaternary structure, but certain peptide hormones and protein complexes require multiple subunits for activity.

Side chain (R group)

The side chain, or R group, is the variable portion of an amino acid that extends from the alpha carbon and determines the amino acid’s chemical character: acidic, basic, polar, nonpolar, or aromatic. Side chains govern how peptides fold, which receptors they bind, and how they behave in solution. The diversity of side chains among the 20 standard amino acids is what gives peptides their functional range.

Dipeptide

A dipeptide is a peptide composed of exactly two amino acid residues linked by a single peptide bond. Dipeptides are among the shortest peptides and are often studied for their bioactivity in absorption, signaling, or flavor science.

Tripeptide

A tripeptide is a peptide composed of three amino acid residues. GHK (glycyl-L-histidyl-L-lysine) is a well-known research tripeptide studied for its role in copper binding and skin biology.

Oligopeptide

An oligopeptide is a peptide of roughly 2 to 20 amino acid residues. Many bioactive research peptides are oligopeptides, including signaling peptides studied in growth hormone and tissue repair research.

Polypeptide

A polypeptide is a longer peptide of more than roughly 20 amino acid residues. The boundary between polypeptide and protein is not strict, but polypeptides are generally considered peptides that have not folded into a stable tertiary structure, while proteins have.

Peptide classes and categories

Bioactive peptide

A bioactive peptide is any peptide that produces a measurable biological effect in a living system or in vitro assay. Bioactive peptides are studied for their receptor binding, signaling activity, and pharmacokinetic behavior. The majority of the Healius research catalog is classified as bioactive peptides.

Therapeutic peptide

A therapeutic peptide is a peptide that has completed regulatory approval for clinical use in humans or veterinary medicine. Therapeutic peptides include finished pharmaceutical products such as semaglutide (Ozempic) and insulin. Research peptides supplied by Healius are not therapeutic peptides and are not approved for human or veterinary use.

Research peptide

A research peptide is a peptide supplied for in vitro laboratory and preclinical research use. Research peptides are not approved for administration to humans or animals and carry mandatory research use only labeling. Every peptide in the Healius catalog is a research peptide and ships with full research-use-only documentation.

Cyclic peptide

A cyclic peptide is a peptide whose backbone or side chains form a closed ring, typically through a disulfide bond, amide bond, or other covalent linkage. Cyclic peptides often show greater metabolic stability and receptor selectivity than linear peptides, making them valuable research tools in pharmacology.

Linear peptide

A linear peptide is a peptide whose backbone runs uninterrupted from N-terminus to C-terminus without ring closure. Most research peptides are linear. Linear peptides are simpler to synthesise but often less metabolically stable than cyclic counterparts.

Peptidomimetic

A peptidomimetic is a molecule designed to mimic the biological activity of a natural peptide while using non-peptide chemical scaffolds for greater stability or oral bioavailability. Peptidomimetics are used in research and drug discovery to overcome the short half-life of natural peptides.

Peptide fragment

A peptide fragment is a shorter peptide sequence derived from a longer parent peptide or protein, often studied to isolate the minimal active domain. Fragment peptides are common tools in receptor mapping and structure-activity relationship research.

Peptide analog

A peptide analog is a peptide whose sequence has been modified from a natural parent to study or enhance specific properties such as receptor selectivity, potency, or metabolic stability. Substituting one amino acid for another (including non-natural amino acids) is the most common analog strategy.

Antimicrobial peptide (AMP)

An antimicrobial peptide is a peptide with broad-spectrum activity against bacteria, fungi, viruses or parasites. AMPs are studied extensively for their role in innate immunity and as templates for novel antimicrobial research.

Neuropeptide

A neuropeptide is a peptide used by neurons for intercellular signaling in the nervous system. Neuropeptides are investigated in research spanning pain modulation, mood regulation, memory, and neuroprotection.

Signal peptide

A signal peptide is a short sequence at the N-terminus of a newly synthesised protein that directs the protein to its cellular destination, typically for secretion. Signal peptides are cleaved off after the protein reaches its target. In research contexts, signal peptide sequences can be isolated and studied independently.

Peptide hormone

A peptide hormone is a peptide produced by the endocrine system that signals between tissues via the bloodstream. Insulin, glucagon, growth hormone-releasing hormone (GHRH) and somatostatin are classical peptide hormones. Many research peptides are structural analogs or fragments of peptide hormones.

Peptide synthesis and modification

Solid-phase peptide synthesis (SPPS)

Solid-phase peptide synthesis is the dominant method for producing research peptides. The peptide is assembled one residue at a time on an insoluble polymer resin, starting from the C-terminus and extending toward the N-terminus. Each cycle adds one protected amino acid, deprotects, washes, and couples the next residue. Invented by Bruce Merrifield in 1963 (Nobel Prize 1984), SPPS enables automated high-purity synthesis of peptides up to roughly 50 residues.

Liquid-phase peptide synthesis

Liquid-phase peptide synthesis is the older solution-based approach to peptide synthesis. It is now used primarily for short peptides produced at large scale where SPPS is uneconomic. Most research peptides are produced by SPPS rather than liquid-phase synthesis.

Fmoc chemistry

Fmoc (9-fluorenylmethoxycarbonyl) is a protecting group used on the alpha-amino group during solid-phase peptide synthesis. Fmoc is removed with mild base (piperidine) between coupling cycles. Fmoc chemistry has become the SPPS standard because of its compatibility with acid-labile side-chain protecting groups and its cleaner deprotection profile.

Boc chemistry

Boc (tert-butoxycarbonyl) is an alternative alpha-amino protecting group in solid-phase peptide synthesis, removed with trifluoroacetic acid. Boc chemistry was the historical standard for SPPS and is still used for certain peptide modifications, though Fmoc chemistry is more common today.

Resin

A resin is the insoluble polymer support on which solid-phase peptide synthesis is performed. Common resin chemistries include Wang resin (for acid-cleavable peptides with free C-terminus) and Rink amide resin (for C-terminally amidated peptides). The choice of resin determines the C-terminal chemistry of the final peptide.

Coupling agent

A coupling agent is a reagent that activates the carboxyl group of an incoming amino acid for peptide bond formation during synthesis. HBTU, HATU, and DIC are common coupling agents. Coupling efficiency directly affects the purity of the final synthesised peptide.

Deprotection

Deprotection is the removal of temporary protecting groups from an amino acid side chain or alpha-amino group during peptide synthesis. Accurate deprotection is essential: incomplete deprotection leads to deletion sequences, and premature deprotection leads to side-chain aggregation.

Acetylation

Acetylation is the addition of an acetyl group (CH3CO) to the N-terminus of a peptide. N-terminal acetylation is a common modification that increases peptide stability by masking the free amino group from proteases and alters pharmacokinetic properties. Acetylated peptides are frequently studied in pharmacology and neuroscience research.

Amidation

Amidation is the conversion of a peptide’s C-terminal carboxyl group (COOH) to an amide group (CONH2). C-terminal amidation is naturally occurring in many peptide hormones and is a common research modification that improves stability and receptor binding profiles. Amidated peptides are denoted with “NH2” at the C-terminus (for example, GHRP-6-NH2).

Pegylation

Pegylation is the covalent attachment of polyethylene glycol (PEG) chains to a peptide. PEG chains increase molecular weight, reduce renal clearance, and extend half-life. Pegylated research peptides typically show extended plasma residence time compared to their non-pegylated parent peptides.

Lipidation

Lipidation is the attachment of a fatty acid chain to a peptide, typically at a lysine side chain or the N-terminus. Lipidation improves peptide binding to serum albumin, which significantly extends half-life. Lipidated peptide analogs are a major class of long-acting peptide research compounds.

Phosphorylation

Phosphorylation is the addition of a phosphate group (PO4) to a serine, threonine, or tyrosine side chain. Phosphorylation is a key post-translational modification in signaling biology and is often synthetically incorporated into research peptides to study signal transduction pathways.

Analytical testing and quality control

HPLC (High-Performance Liquid Chromatography)

HPLC is the reference method for measuring peptide purity. A sample is injected onto a chromatographic column, typically reversed-phase C18, and separated by its interaction with the stationary phase under a controlled solvent gradient. The detector (usually UV at 214 nm or 220 nm) measures peak areas, and the main peak area divided by the total area gives the HPLC purity percentage. HPLC is the primary method behind the 99%+ purity figure reported on every Healius Certificate of Analysis.

UPLC (Ultra-Performance Liquid Chromatography)

UPLC is the higher-resolution successor to HPLC, using smaller particle columns (sub-2-micron) and higher operating pressures to deliver faster runs and better peak separation. UPLC is used when finer resolution of closely eluting impurities is required. Some laboratories now use UPLC as their standard analytical platform for peptide release.

Mass spectrometry (MS)

Mass spectrometry is the reference method for confirming peptide identity. The instrument ionises the peptide, typically by electrospray ionisation (ESI), and measures the mass-to-charge ratio (m/z) of the resulting ions. A pass result requires the measured mass to match the expected mass calculated from the peptide sequence within tolerance (typically plus or minus 0.5 Da). MS is run on every Healius batch alongside HPLC.

Electrospray ionisation (ESI)

Electrospray ionisation is the standard ionisation method used in mass spectrometry of peptides. A liquid sample is sprayed through a charged capillary, producing charged droplets that evaporate to leave gas-phase ions for the mass spectrometer. ESI produces multiply-charged ions of intact peptides without fragmenting the backbone, making it ideal for peptide identity confirmation.

Certificate of Analysis (COA)

A Certificate of Analysis is the signed quality record issued for a specific batch of a research peptide. A complete COA includes peptide identity (confirmed by mass spectrometry), HPLC purity (with chromatogram), lot number, manufacturing date, recommended storage conditions, and the signature of the releasing analyst. Every Healius peptide ships with a batch-specific COA, and every COA is available to look up on the Lab Testing page /lab-testing/. For a field-by-field walkthrough see /lab-testing/.

HPLC purity

HPLC purity is the percentage of the total peak area on an HPLC chromatogram attributable to the target peptide. A 99% HPLC purity reading means that 99% of the UV-absorbing material in the sample elutes as the main peak, with the remaining 1% distributed across smaller peaks that represent impurities, deletion sequences, or oxidation products. 99%+ is the release standard for every Healius research peptide.

Impurity profile

An impurity profile is the catalog of minor peaks detected on an HPLC chromatogram of a peptide sample. Common impurities include deletion sequences (missing one amino acid), truncation sequences, oxidation products (especially on methionine and cysteine residues), and residual synthesis reagents. A quality Certificate of Analysis reports not just the main peak percentage but also the identity and size of significant impurities.

Third-party testing

Third-party testing is the independent verification of a peptide batch by a laboratory unrelated to the supplier, using different instruments and reagents. Third-party testing exposes systematic bias in in-house analysis and is considered the highest standard for peptide quality documentation. Every Healius batch is verified by an ISO 17025 accredited third-party laboratory. See /lab-testing/ for programme detail.

ISO 17025

ISO/IEC 17025 is the international standard for the competence of testing and calibration laboratories. Accreditation to ISO 17025 requires documented evidence of technical competence, impartiality, quality management, and the traceability of analytical results. Healius commissions third-party peptide testing only from ISO 17025 accredited laboratories.

Karl Fischer titration

Karl Fischer titration is the reference method for measuring water content in a lyophilised peptide. A small sample is dissolved in methanol and titrated against Karl Fischer reagent, which reacts stoichiometrically with water. Accurate water content measurement is important for calculating net peptide content per vial and for characterising stability.

Storage, handling and reconstitution

Lyophilisation (freeze-drying)

Lyophilisation is the process of removing water from a peptide solution by freezing the solution and then sublimating the ice under vacuum. The result is a dry, porous peptide cake that is stable for long-term storage at low temperatures. All Healius peptides are supplied as lyophilised powders.

Lyophilised peptide

A lyophilised peptide is the freeze-dried solid form of a peptide, typically appearing as a white or off-white cake inside a sealed amber glass vial. Lyophilised peptides are the most stable form for long-term storage and are shipped at ambient temperature in insulated packaging. Lyophilised peptides must be reconstituted with a compatible solvent before research use.

Reconstitution

Reconstitution is the process of dissolving a lyophilised peptide in a compatible solvent to create a working research solution. The standard solvent is bacteriostatic water, typically added slowly down the inside wall of the vial followed by gentle swirling. For exact reconstitution volume guidance, see the Healius Peptide Reconstitution Calculator /calculator/ and the full Reconstitution and Storage Guide /reconstitution-storage/.

Bacteriostatic water

Bacteriostatic water is sterile water containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol inhibits bacterial growth in the reconstituted peptide solution, which allows a multi-dose vial to be used across its shelf life without microbial contamination. Bacteriostatic water is the default solvent for the majority of research peptides.

Acetic acid (reconstitution solvent)

Dilute sterile acetic acid (typically 0.6%) is the reconstitution solvent of choice for hydrophobic peptides that do not fully dissolve in bacteriostatic water. Acetic acid disrupts hydrogen bonding and aids peptide dissolution. After initial reconstitution, the solution can often be diluted with PBS or bacteriostatic water for the working assay.

Freeze-thaw cycle

A freeze-thaw cycle is one complete transition of a peptide solution from frozen to thawed and back. Every freeze-thaw cycle causes measurable purity loss (typically 1 to 5% per cycle depending on peptide chemistry). Best practice is to aliquot reconstituted peptides into single-use volumes before freezing so each aliquot is thawed only once.

Shelf life

Shelf life is the period over which a peptide is expected to retain specified purity under defined storage conditions. Lyophilised peptides typically have a shelf life of 24 to 48 months at minus 20 degrees Celsius. Reconstituted peptides typically have a shelf life of 1 to 8 weeks at 2 to 8 degrees Celsius depending on peptide chemistry. The Healius COA reports the specific shelf life for every batch.

Aliquot

An aliquot is a small measured volume of a peptide solution dispensed into a separate single-use container before freezing. Aliquotting is the standard strategy to minimise freeze-thaw damage: each aliquot is thawed once, used for a single research draw, and discarded. Aliquots are typically stored in sterile amber microcentrifuge tubes at minus 20 degrees Celsius or colder.

Sonication

Sonication is the use of high-frequency sound waves to aid dissolution of a peptide into solvent. Sonication is useful for hydrophobic peptides that fail to fully reconstitute by swirling. Low-power, short-duration sonication (30 to 60 seconds) is preferred to avoid heat-induced peptide degradation.

Amber glass vial

An amber glass vial is the standard container for research peptides. The amber colour blocks UV and short-wavelength visible light that can degrade light-sensitive peptides such as those containing tryptophan. The glass wall is non-reactive and does not contribute leachables to the peptide solution.

Research pharmacology and biology

Agonist

An agonist is a molecule that binds a receptor and activates it, producing a biological response. Many research peptides are receptor agonists studied to characterise signaling pathways or to evaluate analog potency relative to endogenous ligands.

Antagonist

An antagonist is a molecule that binds a receptor without activating it, blocking the receptor from being activated by other ligands. Peptide antagonists are used in research to dissect signaling pathways and to evaluate the role of specific receptors in biological processes.

Receptor

A receptor is a protein (typically on the cell surface or inside the cell) that binds a specific ligand and triggers a downstream biological response. Peptide research frequently focuses on G protein-coupled receptors (GPCRs), tyrosine kinase receptors, and nuclear receptors.

Ligand

A ligand is any molecule that binds a receptor. Ligands include endogenous peptides, synthetic peptide analogs, small molecules, and neurotransmitters. Ligand-receptor binding is the fundamental event in peptide pharmacology research.

Binding affinity

Binding affinity is the strength with which a ligand binds its receptor, usually expressed as the dissociation constant (Kd) or half-maximal effective concentration (EC50). Lower Kd values indicate higher affinity. Binding affinity is a primary endpoint in peptide structure-activity relationship studies.

Half-life (t1/2)

Half-life is the time required for the concentration of a peptide in a biological system to fall to 50% of its initial value. Peptide half-life depends on rate of proteolysis, rate of renal clearance, and (where present) binding to serum proteins. Natural peptides often have short half-lives (minutes), while modified peptide analogs can have half-lives extended to hours or days through pegylation or lipidation.

Bioavailability

Bioavailability is the fraction of an administered peptide that reaches the systemic circulation in a form available to exert activity. Most peptides have very low oral bioavailability due to gastrointestinal proteolysis and poor membrane permeability. Parenteral administration routes (subcutaneous, intravenous, intramuscular) are used in research to bypass oral limitations.

Pharmacokinetics (PK)

Pharmacokinetics is the study of how a peptide is absorbed, distributed, metabolised and eliminated over time. Peptide PK is dominated by proteolytic degradation and renal clearance. Modifying a peptide to extend half-life (through pegylation, lipidation, or structural rigidification) is a primary focus in peptide drug discovery research.

Signaling pathway

A signaling pathway is the chain of molecular events that follows ligand binding to a receptor and produces a cellular response. Peptide research frequently focuses on characterising which signaling pathways a peptide activates, and at what potency, to understand its biological mechanism.

In vitro

In vitro (Latin for “in glass”) refers to experiments performed outside a living organism, typically in cell culture, cell-free assays, or isolated tissue preparations. All research peptides supplied by Healius are for in vitro use only and are not intended for administration to humans or animals.

Regulatory, compliance and labelling

Research Use Only (RUO)

Research Use Only is a regulatory designation indicating that a product is intended for laboratory and research investigation only and is not approved for human or veterinary administration, clinical diagnosis, or therapeutic use. Every Healius peptide carries RUO labelling on the vial, the packing slip, and the Certificate of Analysis.

GMP (Good Manufacturing Practice)

Good Manufacturing Practice is a regulatory framework governing the manufacture of finished pharmaceutical products. GMP defines documented procedures for raw materials, facilities, equipment, personnel, quality control, and record keeping. Research peptides are not manufactured under GMP (GMP is reserved for medicines intended for human use). Healius manufacturing partners operate under GMP-aligned quality systems where applicable, but Healius peptides are not GMP products.

ISO 9001:2015

ISO 9001:2015 is the international standard for quality management systems. Organisations certified to ISO 9001:2015 demonstrate documented control over their processes, products and continuous improvement activities. Healius operations are aligned with ISO 9001:2015 principles across sourcing, synthesis, testing and fulfilment.

FDA

The US Food and Drug Administration is the federal regulatory agency responsible for protecting public health through regulation of drugs, medical devices, foods, and cosmetics in the United States. Research peptides supplied for in vitro use are not FDA approved for human or veterinary use. Statements made about Healius peptides have not been evaluated by the FDA.

TGA

The Therapeutic Goods Administration is Australia’s federal regulator of therapeutic goods, including medicines and medical devices. Research peptides sold for in vitro use are not TGA-approved for human or veterinary administration. Australian buyers are responsible for ensuring compliance with TGA regulations.

MHRA

The Medicines and Healthcare products Regulatory Agency is the UK’s regulator of medicines, medical devices, and blood components. Research peptides sold for in vitro use are not MHRA-authorised under the Human Medicines Regulations 2012. UK buyers are responsible for ensuring compliance with MHRA regulations.

Batch (lot) number

A batch number, also called a lot number, is a unique identifier assigned to a single production run of a peptide. The batch number on the vial label corresponds to the batch-specific Certificate of Analysis. Batch numbers are the key to full traceability from synthesis to the vial in your lab and are required on every research notebook entry for reproducibility.

Deletion sequence

A deletion sequence is a peptide in which one or more amino acid residues from the intended sequence are missing, produced when a coupling cycle fails during solid-phase peptide synthesis. Deletion sequences are the most common impurity class in synthetic research peptides. A strong HPLC method separates the intended peptide from deletion sequences, and the main peak percentage reported as HPLC purity reflects this separation.

Truncation sequence

A truncation sequence is a peptide that stopped short of the full target length during solid-phase synthesis. Truncation products are flagged and removed during downstream purification, and their residual presence contributes to the impurity percentage on the Certificate of Analysis.